Mycological study of Zygomycosis in patient suffering from suspected Mucormycosis during COVID-19 pandemic at IGIMS, Patna
Keywords:
Zygomycosis, mucormycosis, diabetes, Rhizopus, proptosisAbstract
Aim: To study the speciation of zygomycosis, associated risk factors and spectrum of other fungus isolated in patients of suspected mucormycosis. Methodology: A prospective observational cross-sectional study was conducted for duration of 6 months in the Department of Microbiology, IGIMS, Patna. All the patients suspected clinically with mucormycosis visiting IGIMS, Patna were included in this study. Patient details were taken from lab investigation form after taking informed consent form from the patients or close relatives. Specimens were collected and routine microscopy (KOH mount), grams stain and culture was done for all samples. All the demographic details, laboratory results, clinical symptoms, COVID-19 status, systemic history, treatment history details were collected and analysed. Results: Out of 203 patients, 72.4% were males and 27.6% were females. Mean age of the patients was 50.19 + 3.08 years. 51.2% were KOH positive and 48.8% were KOH negative. In culture method, 28.6% had Rhizopusspp, 17.7% had Aspergillus spp, 17.7% had Candida spp, and 43.8% had no growth. 27.1% patients were either COVID positive during examination or had COVID history in recent time. Out of 55 patients (27.1%) having/had COVID history, only 54.5% were KOH positive and 41.8% were Rhizopusspp positive culture.
Downloads
References
Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021 Apr;42:264.e5-264.e8.
Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020 Mar 27;12(4):372.
Paltauf A. Mycosis mucorina. Virchows Arch Pathol Anat Physiol Klin Med 1885;102:543–64
Baker RD. Mucormycosis-a new disease? J Am Med Assoc. 1957;163:805-808.
Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses. 2001;44(7):253-260.
Sugar AM. In: Mandell GL, Bennett JE, Dolin R(eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases (5th edn), Churchill Livingstone, New York, USA, 2000.
Pemán J, Ruiz-Gaitán A, García-Vidal C, Salavert M, Ramírez P, Puchades F, García-Hita M, Alastruey-Izquierdo A, Quindós G. Fungal co-infection in COVID-19 patients: Should we be concerned? Rev Iberoam Micol. 2020 Apr-Jun;37(2):41-46.
Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, Simeo R, Buselli A, Rizzo D, Bussu F, Rubino S, Terragni P. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2021 Oct;49(5):1055-1060.
Hernández JL, Buckley CJ. Mucormycosis. [Updated 2022 Apr 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544364/.
Sugar AM. Mucormycosis. Clin Infect Dis. 1992 Mar;14 Suppl 1:S126-9.
Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope. 1997 Jul;107(7):855-62.
Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, Pamidimukkala U, Jillwin J, Varma S, Das A, Panda NK, Singh S, Bal A, Chakrabarti A. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol. 2019 Jun 1;57(4):395-402.
Patel A, Kaur H, Xess I, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. ClinMicrobiol Infect. 2020;26(7):944.e9-944.e15.
Bala K, Chander J, Handa U, et al. A prospective study of mucormycosis in north India: experience from a tertiary care hospital. Med Mycol 2015 Apr;53(3):248-57.
John TM, Jacob CN, Kontoyiannis DP. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi (Basel). 2021 Apr 15;7(4):298.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
